anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cardiac Electrophysiology

At a dose of cabotegravir 150 mg orally every 12 hours (10 times the recommended total daily oral lead-in dosage of CABENUVA), the QT interval is not prolonged to any clinically relevant extent. Administration of 3 doses of cabotegravir 150 mg orally every 12 hours resulted in a geometric mean Cmax approximately 2.8-, 5.4-, and 5.6-fold above the geometric mean steady-state Cmax associated with the recommended 30‑mg dose of oral cabotegravir, the recommended 400‑mg dose given monthly, and the recommended 600-mg dose given every 2 months of cabotegravir extended-release injectable suspension, respectively. 

At the recommended dose of rilpivirine 25 mg orally once daily, the QT interval is not prolonged to any clinically relevant extent. The rilpivirine 25-mg once-daily mean steady-state Cmax was 247 ng/mL, which is 1.7-fold higher than the mean steady-state Cmax observed with the recommended 600-mg dose of rilpivirine extended-release injectable suspension given monthly and 1.6-fold higher than the mean steady-state Cmax observed with the recommended 900-mg dose of rilpivirine extended-release injectable suspension given every 2 months. 

When rilpivirine 75-mg and 300-mg once-daily oral doses (3 and 12 times, respectively, the recommended oral lead-in dosage) were studied in healthy adults, the maximum mean time-matched (95% upper confidence bound) differences in QTcF interval were 10.7 (15.3) and 23.3 (28.4) msec, respectively, after baseline and placebo adjustment. Steady-state administration of rilpivirine 75 mg once daily and 300 mg once daily resulted in a mean steady-state Cmax approximately 4.4- and 11.6-fold, respectively, higher than the mean steady-state Cmax observed with the recommended 600-mg dose of rilpivirine extended-release injectable suspension given monthly and approximately 4.1- and 10.7-fold, respectively, higher than the mean steady-state Cmax observed with the recommended 900-mg dose of rilpivirine extended-release injectable suspension given every 2 months. The corresponding Cmax ratios are 2.6 and 6.7 when compared with the recommended oral rilpivirine dosage [see Warnings and Precautions (5.5)].
The subject of the present disclosure is a method for dyeing keratinous material, in particular human hair. The method includes applying an agent (a) to the keratinous material. The agent (a) includes one or more organic silicon compound selected from the group of silanes having one, two or three silicon atoms, (a2) a first colorant compound including one or more lenticular substrate platelet-based pigment, and (a3) a second coloring compound. The method further includes applying an agent (b) to the keratinous material. The agent (b) includes at least one sealing reagent. Also disclosed are multi-component packaging unit (kit-of-parts) for dyeing keratinous material.
The selected markers will be validated in patients with ovarian cysts (300 cases )found by ultrasound. The diagnosis accuracy of the markers will be evaluated by comparing with the pathological diagnosis.
Recombinant human tissue plasminogen kinase derivatives(r-PA) for injection: the first intravenous bolus injection of 18mg, after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time. Subjects were closely monitored during the treatment period and within 24 hours after administration.
Heart failure with preserved ejection fraction (HFpEF) is increasingly recognised and diagnosed in clinical practice, a trend driven by an ageing population and a rise in contributing comorbidities, such as obesity and diabetes. Representing at least half of all heart failure cases, HFpEF is recognised as a complex clinical syndrome. Its diagnosis and management are challenging due to its diverse pathophysiology, varied epidemiological patterns, and evolving diagnostic and treatment approaches. This Seminar synthesises the latest insights on HFpEF, integrating findings from recent clinical trials, epidemiological research, and the latest guideline recommendations. We delve into the definition, pathogenesis, epidemiology, diagnostic criteria, and management strategies (non-pharmacological and pharmacological) for HFpEF. We highlight ongoing clinical trials and future developments in the field. Specifically, this Seminar offers practical guidance tailored for primary care practitioners, generalists, and cardiologists who do not specialise in heart failure, simplifying the complexities in the diagnosis and management of HFpEF. We provide practical, evidence-based recommendations, emphasising the importance of addressing comorbidities and integrating the latest pharmacological treatments, such as SGLT2 inhibitors.
The present invention provides a nose allergy water dropping agent for treating allergic rhinitis. Pure Chinese herbal medicine, such as astragalus roots, ledebouriella roots, schizonepeta, xanthium, dahurian angelica roots, pharbitis sed, tribulus terrestris, etc., are used. The immersion, the boiling and the filtration are repeated twice, mixed filter liquid is concentrated, an anticorrosion agent is added for standing, clear liquid is taken and bottled, and the present invention is obtained through sterilization. The present invention has the advantages of abundant medicine sources, low cost, simple technology, no toxic side effect, soft medicine performance, little excitation, short use treating courses and obvious effect, and is suitable for children, aged people, infants and pregnant women. The present invention is used for treating for 3 to 5 days, and the curing condition is achieved. The near-term cure rate is 100%, and the long-term cure rate is 80%.
PURPOSE: Several mechanisms have been proposed to explain how mental fatigue degrades sport performance. In terms of endurance performance, a role for an increased perceived exertion has been demonstrated. Using electroencephalography and, more specifically, the movement-related cortical potential (MRCP), the present study explored the neural mechanisms that could underlie the mental fatigue-associated increase in perceived exertion.
METHODS: Fourteen participants (age, 23 ± 2 yr; 5 women, 9 men) performed one familiarization and two experimental trials in a randomized, blinded, crossover study design. Participants had to complete a submaximal leg extension task after a mentally fatiguing task (EXP; individualized 60-min Stroop task) or control task (CON; documentary). The leg extension task consisted of performing 100 extensions at 35% of 1 repetition maximum, during which multiple physiological (heart rate, electroencephalography) and subjective measures (self-reported feeling of mental fatigue, cognitive load, behand motivation, ratings of perceived exertion) were assessed.
RESULTS: Self-reported feeling of mental fatigue was higher in EXP (72 ± 18) compared with CON (37 ± 17; P < 0.001). A significant decrease in flanker accuracy was detected only in EXP (from 0.96 ± 0.03% to 0.03%; P < 0.05). No significant differences between conditions were found in MRCP characteristics and perceived exertion. Specifically in EXP, alpha wave power increased during the leg extension task ( P < 0.01).
CONCLUSIONS: Mental fatigue did not impact the perceived exertion or MRCP characteristics during the leg extension task. This could be related to low perceived exertion and/or the absence of a performance outcome during the leg extension task. The increase in alpha power during the leg extension task in EXP suggests that participants may engage a focused internal attention mechanism to maintain performance and mitigate feelings of fatigue.
PURPOSE:A remedy for mycosis, containing (S)-2-amino-5-hydroxy-4-oxopentanoic acid as an antitubercular agent as an active constituent, and having a structure different from that of the conventional remedy and improved remedial effect with low toxicity. CONSTITUTION:A remedy for mycosis containing (S)-2-amino-5-hydroxy-4- oxopentanoic acid (hereinafter abbreviated to this substance) as an active constituent. This substance is capable of treating very well Candida albicans of mice, and is very useful as t remedy for the mycosis. This substance is a type different from that of the conventional remedy in the chemical structure and is a very specific remedy for the mycosis. The remedy can be administered continuously in a large does due to the low toxicity. The dose is preferably 100-4,000 mg/day.
FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
Aim: To evaluate the costs and consequences of two front-line atrial fibrillation (AF) treatments from Chinese healthcare system perspective: radiofrequency catheter ablation (RFCA) using ThermoCool SmartTouch Catheter guided by Ablation Index (STAI), in comparison to antiarrhythmic drugs (AADs). Patients & methods: We simulated clinical and economic consequences for AF patients initially receiving STAI or AADs using a short-term decision tree model leading to a 10-year long-term Markov model. The model projected both clinical consequences and costs associated with, among others, AF, heart failure (HF), strokes, and deaths due to AF or AF related complications. Data informing the models included combination of a local real-world study and published clinical studies. Results: STAI was advantageous versus AADs on all 4 main clinical outcomes evaluated; AF: 25.83% lower (12.84% vs 38.67%), HF: 2.22% lower (1.33% vs 3.55%), stroke or post stroke: 1.82% lower (10.00% vs 11.82%) and deaths due to AF or AF related complications: 0.64% lower (4.11% vs 4.75%). The average total cost per patient in STAI group was ¥16,682 lower (¥123,124 vs ¥139,806). The one-way sensitivity analysis indicated that the difference in total cost was most sensitive to annual AF recurrence probability in AADs-treated patients. Probabilistic sensitivity analysis indicated a 98.5% probability that RFCA treatment would result in cost savings by the end of the 10th year. Conclusion: Radiofrequency catheter ablation using SmartTouch catheter guided by Ablation Index was superior to AADs as the first-line AF treatment in Chinese setting with better clinical outcomes and at lower costs over a 10-year time horizon.
The long-term goal is to help family caregivers of seriously ill patients be better prepared to serve as surrogate decision-makers when their loved ones can no longer make medical decisions for themselves. Research shows that family caregivers find surrogate decision-making highly stressful and emotionally burdensome, in part because they feel unprepared for surrogate decision-making. To date, no studies have determined which advance care planning (ACP) process best prepares caregivers for this role. The investigators' prior work shows that a computer-based decision aid can help patients make more informed decisions and communicate their wishes more effectively. The investigators now propose to determine if family caregivers of patients with life-threatening illnesses are better prepared for surrogate decision-making: 1) when they engage in a structured ACP process together with patients; and 2) when they use this online decision aid for ACP. This will be accomplished via a randomized, controlled trial with a 2 x 2 factorial design comprising 4 groups: Standard ACP/Patient Alone (Group 1), Decision Aid/Patient Alone (Group 2), Standard ACP/Patients and Caregivers Together (Group 3), and Decision Aid/Patients and Caregivers Together (Group 4).
Intestinal barrier dysfunction frequently occurs as a complication in cases of severe acute pancreatitis (SAP); however, no effective therapeutic methods are available because the precise mechanism remains obscure. Recent research has elucidated the role of circulating exosomes in the progression of SAP. Therefore, the present study explored whether inhibiting circulating exosomes release would improve intestinal barrier injury triggered via SAP and investigated the possible underlying mechanism. In vivo, we found that circulating exosomes release exhibited a considerable increase in SAP rats than in SO rats, and GW4869, a suppressor of exosomes release, significantly decreased exosomes release in SAP rats. We also observed that GW4869 suppressed NLRP3 inflammasome-mediated pyroptosis within the intestine and alleviated intestinal barrier injury within SAP. Moreover, the inflammatory response and remote organ (kidney and lung) injury associated with SAP improved after GW4869 treatment. In vitro, we confirmed that depletion of exosomes with GW4869 could partially abolish the destructive effects of SAP rat plasma on the viability and barrier function of IEC-6 cells. In summary, our findings show that the suppression of the release of circulating exosomes effectively inhibits the process of pyroptosis mediated by the NOD-like receptor protein 3 (NLRP3) inflammasome and, therefore, mitigates intestinal barrier dysfunction in SAP, suggesting that circulating exosomes may be a potential target for treating SAP.
FIELD: medicine. SUBSTANCE: combined pharmaceutical preparation includes 250-20000 U erythropoietin (EPO) in separate medicinal forms and 5-20 mg iron (III) complex, moreover, EPO-preparation and iron complex could be represented both in separate medicinal forms or in a single form. The preparation favors for considerable increase of erythrocytic number. The suggested preparations could be used to treat anemic patients or those with indication for hemodialysis. EFFECT: higher efficiency. 4 cl
Objective -- to determine whether an anti-static chamber increases the one-hour steady-state fluticasone plasma concentration, which is an indirect measure of airway delivery and direct measure of systemic exposure. Twelve children 1-6 yrs with well-controlled persistent asthma were treated with HFA-FP pMDI, 2 actuations of 110 µg twice daily. The drug was administered by conventional polycarbonate or anti-static valved-holding chambers with masks in an unblinded, randomized, crossover manner each for at least three days. A blood sample was collected one hour after the last dose when adherence documented by electronic monitor was 100%. FP plasma concentrations were measured by liquid chromatography mass spectrometry assay. Results evaluated using regression analysis.
A calcium magnesium tablet is provided and is a latest product invented at present. Heartburn is one most common problem of gastrointestinal diseases, and occurs mainly associated with the function of the sphincter at the separation place of lower esophagus and stomach. Under normal circumstances, the sphincter is in a relaxed state when people swallow, so that foods smoothly reach the stomach for digestion through the esophagus. Heartburn is a burning feeling resulted from sensitive cells, and is a symptom of case often caused by natural reflux of gastric acid to the esophagus. The calcium magnesium tablet is prepared from cuttlebone, high-calcium powder, magnesium chloride, sodium bicarbonate, and vitamin U, and plays the roles of gastric acid secretion inhibition, gastric mucosa protection, and stomach acid neutralization. People who suffer from heartburn phenomena can take the calcium magnesium tablets which have a significant therapeutic effect.
The utilization of nutraceutical sources such as apple (Malus domestica Borkh) pomace powder (APP) could be a strategy to reduce the excessive disposal of this agro-waste in landfills and promote sustainable Jumbo quail (Coturnix sp.) production. However, the amount of the APP that can be included in Jumbo quail diets to achieve optimum production is unknown. This study evaluated the impact of including incremental levels of APP on performance metrics, haemato-biochemical parameters, and meat quality responses in Jumbo quail. A total of 350 Jumbo quail (7-day-old; 28.0 ± 0.817 g live weight) were weighed and randomly allotted to five dietary treatments, where each treatment had seven replicates with 10 birds each. The diets were formulated to contain 0, 25, 50, 75, and 100 g/kg APP. Dietary APP induced negative quadratic effects (p < 0.05) on feed intake in weeks 2 and 3. Body weight gain and gain-to-feed ratio decreased linearly in weeks 2, 3, and 4, but quadratically responded to APP levels in week 5. Platelets, heterophils, lymphocytes, and serum phosphorus and calcium showed linear or quadratic responses (p < 0.05) as APP levels increased. Increasing levels of APP linearly (p < 0.05) reduced carcass performance and 24-hour breast meat redness and chroma values but increased 1-hour yellowness and 24-hour lightness. The inclusion of APP compromised growth and carcass performance in young growing Jumbo quail. However, feed efficiency and final body weight were maximized between 50 and 75 g APP levels/kg diet in five-week-old Jumbo quail without compromising blood and meat quality parameters.
OBJECTIVES: Residual varus after total knee arthroplasty (TKA) can affect functional outcomes, which may worsen in the presence of obesity. However, no studies were found to compare the outcomes of obese patients involving postoperative residual mild varus or neutral. The aim of this study was to compare postoperative complications and prosthesis survival, and functional outcomes for knees of obese patients with neutral or mild varus after TKA.
METHODS: We retrospectively reviewed 188 consecutive obese patients (body mass index ≥30 kg/m2) at our hospital who underwent TKA due to varus knee osteoarthritis from January 2010 to December 2015. The mechanical hip-knee-ankle axis angle was measured in all patients at admission and discharge. Knee functions were retrospectively assessed based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, Knee Society Knee Score (KS-KS), Knee Society Function Score (KS-FS), Forgotten Joint Score (FJS), and range of motion (ROM). Continuous data were compared between knees with neutral or mild varus alignment using analysis of Student's t test or variance or the Kruskal-Wallis test as appropriate. For multiple comparisons of outcomes, we used Bonferroni-Dunn method to adjust p-values. Categorical data were compared using the chi-squared test.
RESULTS: Of the 156 knees in 137 obese patients who completed follow-up for a mean of 8.32 ± 1.47 years, 97 knees were corrected from varus to neutral and 54 knees were kept in mild residual varus. Patients with mild varus knees had significantly WOMAC (8.25 ± 8.637 vs. 14.97 ± 14.193, p = 0.009) and better FJS (86.03 ± 15.607 vs. 70.22 ± 30.031, p = 0.002). The two types of knees did not differ significantly in KS-KS, KS-FS, or ROM. Although one patient with a neutral knee had to undergo revision surgery, there was no significant difference between two groups.
CONCLUSIONS: For obese patients with osteoarthritis, preservation of residual varus alignment after TKA can improve functional outcomes without compromising prosthesis survival.
The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and \> 7 days as prolonged LOS.
This is a multicenter, randomized (study medication assigned by chance), active-controlled, parallel, 3-arm study. Patients will be randomly (allocation to treatments available by chance) assigned in 3:5:5 ratio to receive one of three treatments groups. The three treatment groups are: Group 1 - CNTO 1275 45 mg dosing at weeks 0 and 4, Group 2 - CNTO 1275 90 mg dosing at weeks 0 and 4, Group 3 - Etanercept 50 mg two times per week through week 12. The total duration for each participant will be up to 64 weeks (approximately 16 months). The active-controlled portion of the study is from Week 0 to Week 12 during which the efficacy and safety of etanercept and 2 dose levels of CNTO 1275 will be evaluated. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment. Patients will receive 2 subcutaneous injections of CNTO 1275 (either 45 or 90 mg doses) or twice weekly injections of etanercept during the first twelve weeks of the study. Patients may receive two additional doses of CNTO 1275 (either 45 or 90 mg doses) up to week 44.
The study will enroll 20 eligible subjects who will receive NK cell infusion to test whether infusion of expanded activated NK cells can produce measurable clinical responses in patients with AML/MDS or T-ALL.The study aims to infuse a target dose of 10 x 107 CD56+ cells/kg, however, as the actual cell dose obtained will vary depending on the donor harvest, the accepted range for cell infusion will be 0.5-20 x 107 CD56+ cells/kg. On day -10, eligible donors (adult family member of recipient) will undergo apheresis once. A second apheresis procedure may be needed to obtain the required cell count from the donor. NK cells will be expanded in co-culture with irradiated (100 Gy) K562-mb15-41BBL cells in closed culture containers for 10 days. Prior to NK cell infusion on Day 0, recipients will undergo screening evaluations and will receive cyclophosphamide, Fludarabine, IL-2, and supportive medications (e.g. mesna). Cytokine regimen of IL-2 will be initiated on the evening of day -1 (dose 1 of 6). IL-2 will be continued at a dose of 1 million units/m2 subcutaneously 3 times per week for 2 weeks (6 doses total). Post-infusion follow-up procedures for up to 1 year from the day of NK cell infusion include physical examination, Complete Blood Count, and metabolic/chemistry studies. The effects of NK cell infusion will also be determined by comparing MRD levels before and after treatment. MRD blood and bone marrow levels will be collected at baseline and at specified time points (until 1 year from the day of NK cell infusion). NK cell donors will be recruited from the family members of the patient recipient. Potential donors aged 21 years old will be consented and will undergo the required screening tests and human leukocyte antigen (HLA) typing. Since 20 eligible subjects will be enrolled as NK cell recipients, 20 donors will also be recruited for this study. Ineligible NK cell donors will have to be replaced.